191 related articles for article (PubMed ID: 34890875)
21. Microfluidic Approaches for the Characterization of Therapeutic Proteins.
Kopp MRG; Arosio P
J Pharm Sci; 2018 May; 107(5):1228-1236. PubMed ID: 29325925
[TBL] [Abstract][Full Text] [Related]
22. Development of a high-throughput solubility screening assay for use in antibody discovery.
Chai Q; Shih J; Weldon C; Phan S; Jones BE
MAbs; 2019; 11(4):747-756. PubMed ID: 30913963
[TBL] [Abstract][Full Text] [Related]
23. Computational tool for the early screening of monoclonal antibodies for their viscosities.
Agrawal NJ; Helk B; Kumar S; Mody N; Sathish HA; Samra HS; Buck PM; Li L; Trout BL
MAbs; 2016; 8(1):43-8. PubMed ID: 26399600
[TBL] [Abstract][Full Text] [Related]
24. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.
Tomar DS; Li L; Broulidakis MP; Luksha NG; Burns CT; Singh SK; Kumar S
MAbs; 2017 Apr; 9(3):476-489. PubMed ID: 28125318
[TBL] [Abstract][Full Text] [Related]
25. High-concentration protein formulations: How high is high?
Garidel P; Kuhn AB; Schäfer LV; Karow-Zwick AR; Blech M
Eur J Pharm Biopharm; 2017 Oct; 119():353-360. PubMed ID: 28690199
[TBL] [Abstract][Full Text] [Related]
26. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
[TBL] [Abstract][Full Text] [Related]
27. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity.
Kumar S; Roffi K; Tomar DS; Cirelli D; Luksha N; Meyer D; Mitchell J; Allen MJ; Li L
Protein Eng Des Sel; 2018 Jul; 31(7-8):313-325. PubMed ID: 30189027
[TBL] [Abstract][Full Text] [Related]
28. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
29. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
[TBL] [Abstract][Full Text] [Related]
30. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
[TBL] [Abstract][Full Text] [Related]
31. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
[TBL] [Abstract][Full Text] [Related]
32. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
33. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering.
Geoghegan JC; Fleming R; Damschroder M; Bishop SM; Sathish HA; Esfandiary R
MAbs; 2016 Jul; 8(5):941-50. PubMed ID: 27050875
[TBL] [Abstract][Full Text] [Related]
34. Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies.
Mock M; Jacobitz AW; Langmead CJ; Sudom A; Yoo D; Humphreys SC; Alday M; Alekseychyk L; Angell N; Bi V; Catterall H; Chen CC; Chou HT; Conner KP; Cook KD; Correia AR; Dykstra A; Ghimire-Rijal S; Graham K; Grandsard P; Huh J; Hui JO; Jain M; Jann V; Jia L; Johnstone S; Khanal N; Kolvenbach C; Narhi L; Padaki R; Pelegri-O'Day EM; Qi W; Razinkov V; Rice AJ; Smith R; Spahr C; Stevens J; Sun Y; Thomas VA; van Driesche S; Vernon R; Wagner V; Walker KW; Wei Y; Winters D; Yang M; Campuzano IDG
MAbs; 2023; 15(1):2256745. PubMed ID: 37698932
[TBL] [Abstract][Full Text] [Related]
35. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
[TBL] [Abstract][Full Text] [Related]
36. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
[TBL] [Abstract][Full Text] [Related]
37. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
38. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies.
Samra HS; He F
Mol Pharm; 2012 Apr; 9(4):696-707. PubMed ID: 22263524
[TBL] [Abstract][Full Text] [Related]
39. A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development.
Toprani VM; Joshi SB; Kueltzo LA; Schwartz RM; Middaugh CR; Volkin DB
J Pharm Sci; 2016 Aug; 105(8):2319-27. PubMed ID: 27368120
[TBL] [Abstract][Full Text] [Related]
40. High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum.
Li X; Geng SB; Chiu ML; Saro D; Tessier PM
Bioconjug Chem; 2015 Mar; 26(3):520-8. PubMed ID: 25714504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
